Astra and Daiichi beat Gilead to the punch, at least in one setting.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
After more discontinuations, a new deal brings in fresh blood.
Harmoni-A hits, backing a quiet disclosure about the Harmoni trial.
Inhibrx reveals three deaths in phase 1, but all predate screening protocols.
BG-75202 features among several projects starting first-in-human trials.
There will soon be three PD-(L)1 x VEGF projects in pivotal lung and colorectal cancer trials.
Pfizer cans PF-08046045, but keeps PF-08046044 for now.